Home Cart Sign in  
Chemical Structure| 574013-66-4 Chemical Structure| 574013-66-4

Structure of Fexaramine
CAS No.: 574013-66-4

Chemical Structure| 574013-66-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Fexaramine is a small molecule farnesoid X receptor (FXR) agonist with 100-fold increased affinity relative to natural compounds.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Fexaramine

CAS No. :574013-66-4
Formula : C32H36N2O3
M.W : 496.64
SMILES Code : O=C(OC)/C=C/C1=CC=CC(N(CC2=CC=C(C3=CC=C(N(C)C)C=C3)C=C2)C(C4CCCCC4)=O)=C1
MDL No. :MFCD09971007
InChI Key :VLQTUNDJHLEFEQ-KGENOOAVSA-N
Pubchem ID :5326713

Safety of Fexaramine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H413
Precautionary Statements:P301+P312+P330

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Wild-type C57BL/6J mice and db/db mice Oral gavage 50 mg/kg Once a day for 7 to 9 days FEX markedly increased taurolithocholic acid (TLCA), increased fibroblast growth factor 15 (FGF15) and FGF21 and GLP-1 secretion, improved insulin and glucose tolerance, and promoted white adipose tissue browning in mice. Hepatology. 2018 Oct;68(4):1574-1588
C57BL/6 mice Alcoholic liver disease model Oral gavage 100mg/kg BW Daily for 8 weeks To evaluate the protective effect of Fexaramine on alcoholic liver disease. Results showed that Fexaramine reduced ethanol-induced liver injury and steatosis, decreased hepatic inflammatory markers IL1B and TNF protein expression, and stabilized gut barrier function. Hepatology. 2018 Jun;67(6):2150-2166
Mice High-fat diet-induced metabolic syndrome model Gavage 100 mg/kg/day Once daily for 6 weeks To evaluate whether Fexaramine affects the amelioration of metabolic syndrome by reversing the inhibitory effect of tryptophan on intestinal FXR signaling. Results showed that Fexaramine reversed the Trp-induced reduction in FGF15 protein levels and the Trp-induced increase in BA levels. Research (Wash D C). 2024 Dec 13;7:0515
Mice High-fat diet-induced NASH model Dietary administration 50 mg/kg body weight/day Daily administration for 3 weeks Evaluate the effect of Fexaramine on NASH and metabolic disorders. Results showed that Fexaramine did not significantly increase FXR activation, did not raise TGR5 ligands, did not modulate TGR5 signaling, and did not regulate GLP-1 secretion. Nutrients. 2022 Jun 29;14(13):2707
Mice High-fat diet-induced obesity model Oral gavage 50 mg or 100 mg/kg body weight Once daily for 5 weeks Fexaramine reduces diet-induced weight gain and metabolic syndrome by promoting energy expenditure and browning of white adipose tissue. Nat Med. 2015 Feb;21(2):159-65

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.01mL

0.40mL

0.20mL

10.07mL

2.01mL

1.01mL

20.14mL

4.03mL

2.01mL

References

 

Historical Records

Categories